Results 211 to 220 of about 7,749,363 (311)

Author Correction: NRF1-mediated innate immune response drives inflammaging. [PDF]

open access: yesNat Commun
Lei H   +18 more
europepmc   +1 more source

Choroid Plexus Enlargement and USPIO‐Based Inflammatory Feature in Cerebral Small Vessel Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The choroid plexus (CP) is a key component of the blood–cerebrospinal fluid barrier (BCSFB), but its mechanism of action in cerebral small vessel disease (CSVD) remains unclear. This study investigated CP volume (CPV) alterations and their association with conventional imaging markers in CSVD and explored the underlying role of ...
Yongqiang Qu   +11 more
wiley   +1 more source

An Integrated Analysis to Understand the Dysregulation of Innate Immune Response in Mouse Models of MASLD. [PDF]

open access: yesCells
Goswami Y   +12 more
europepmc   +1 more source

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec   +6 more
wiley   +1 more source

Obesity exacerbates giardiasis: metabolic, intestinal, and immune response in high-fat diet-fed gerbils. [PDF]

open access: yesBraz J Med Biol Res
Ventura LLA   +7 more
europepmc   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

Addendum: Neural anticipation of virtual infection triggers an immune response. [PDF]

open access: yesNat Neurosci
Trabanelli S   +18 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy